Surrozen SRZN 深 沪
已收盘 09-25 16:00:00 美东时间
29.54
-4.140
-12.29%
华盛通- 最 高37.83
- 今 开34.72
- 成交量 192.96万股
- 最 低 28.55
- 昨 收 33.68
- 总市值 3.47亿
- 52周最高 37.83
- 市盈率 静 --
- 换手率 16.42%
- 52周最低 11.39
- 委 比 -88.68%
- 总股本 1175.36万
- 历史最高 210.00
- 量 比 0.80
- 振 幅 27.55%
- 历史最低 4.50
- 每 手 1
- 风险率 5.52%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多HC Wainwright & Co. Maintains Buy on Surrozen, Raises Price Target to $54
HC Wainwright & Co. analyst Matthew Caufield maintains Surrozen (NASDAQ:SRZN) with a Buy and raises the price target from $44 to $54.
09-25 19:52
Surrozen Gains Momentum as FDA Submission Opens Path for Lead Therapy
Surrozen Inc. (NASDAQ:SRZN) skyrocketed on Thursday after the company submitted an Investigational New Drug application to the U.S. Food and Drug Administration to evaluate SZN-8141 for treating diabetic macular edema. The biotechnology company aims to advance the investigational therapy into clinic...
09-24 23:41
Surrozen Submits IND Application To FDA Seeking To Evaluate SZN-8141, Bifunctional Wnt Agonist And Vascular Endothelial Growth Factor Antagonist Antibody, For Treatment Of Diabetic Macular Edema
Surrozen, Inc. (Surrozen or the Company) (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced the submission of an Investigational New Dru...
09-08 20:32
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
HC Wainwright & Co. Reiterates Buy on Surrozen, Maintains $44 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Surrozen (NASDAQ:SRZN) with a Buy and maintains $44 price target.
08-10 18:29
美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
Surrozen shares are trading lower after the company reported worse-than-expected Q1 EPS results.
Surrozen shares are trading lower after the company reported worse-than-expecte...
05-08 00:54
HC Wainwright & Co. Maintains Buy on Surrozen, Raises Price Target to $44
HC Wainwright & Co. analyst Matthew Caufield maintains Surrozen (NASDAQ:SRZN) with a Buy and raises the price target from $36 to $44.
05-07 19:09
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
TD Cowen Initiates Coverage On Surrozen with Buy Rating
TD Cowen analyst Phil Nadeau initiates coverage on Surrozen (NASDAQ:SRZN) with a Buy rating.
04-22 00:33
